

# PreveCeutical Medical Inc.

10:28 08 Jan 2020

## PreveCeutical Medical sees positive results from safety appraisal of Sol-Gel formulations in nasal tissue

PreveCeutical Medical Inc (CSE:PREV) (OTCMKTS: PRVCF) said Wednesday that after infusing CBD with its flagship Sol-gel technology and developing water-based cannabis extract-infused soluble gel formulations, it has successfully completed a preliminary safety evaluation of CBD Sol-gel formulations in human nasal mucosal tissue.

In a statement, the Canadian health-sciences company said that over a five-day analysis period, there was no elevation in "clinically accepted" biomarkers of tissue toxicity.

"These results would appear to indicate that the selected CBD Sol-gel formulations that were tested have no acute toxic effects when applied to human nasal mucosal tissue," said the company.

### READ: PreveCeutical Medical successfully infuses CBD with its Sol-gel pain-relief technology

The third and final stage of the Sol-gel program was aimed at assessing and profiling cannabinoid release from the extract infused Sol-gels, as well as evaluating if CBD deposited into nasal mucosal tissue (ex vivo) was tolerated without toxic effects.

"The results from the evaluation indicating no acute toxic effects of the selected CBD Sol-gel formulations on explanted human nasal mucosal tissue is a good finding," said PreveCeutical president and chief science officer Dr Mak Jawadekar.

### Positive results to inspire proof of concept studies

He said it gives the company the confidence to conduct further proof of concept studies.

The Canadian health-sciences company is developing the sustained-release Sol-gel program for the delivery of medical compounds, including cannabinoids like CBD, to provide relief from pain, inflammation, seizures and neurological disorders.

With the use of an applicator, Sol-gels are taken via the nose and rapidly gel upon contact with mucosal tissue.

### Advantages of CBD Sol-gel formulations

The CBD Sol-gel formulations are expected to allow for the direct and prolonged delivery of cannabinoids to a patients' central nervous system.

Future studies, outside of the current Sol-gel program, may involve pre-clinical/clinical evaluation of the CBD Sol-gel formulations as the company's medicinal cannabis division hopes to offer a broad product range of formulations that can be tailored to specific medical conditions.

**Price:** 0.04

**Market Cap:** \$19.68 m

#### 1 Year Share Price Graph



September 2019 March 2020 September 2020

#### Share Information

**Code:** PREV

**Listing:** CSE

**52 week High Low**  
0.1 0.01

**Sector:** Medical technology & services

**Website:** preveceutical.com

#### Company Synopsis:

*PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilising organic and nature identical products.*

action@proactiveinvestors.com

PreveCeutical, based in Vancouver, is also advancing non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone, and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

Contact the author Uttara Choudhury at [uttara@proactiveinvestors.com](mailto:uttara@proactiveinvestors.com)

Follow her on Twitter: @UttaraProactive

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc. named herein, including the promotion by the Company of PreveCeutical Medical Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).